Koristiti opciju "Traži" pre postavljanja nove tem
Moderatori: mr ph. Silvio, ModeratA, moderato, admin, vlada99
-
admin
- doktor.rs tim
- Postovi: 403
- Pridružio se: Uto Avg 14, 2001 2:00 am
- Koliki je zbir brojeva cetiri i pet: 5
- Lokacija: Beograd
- Kontakt:
Koristiti opciju "Traži" pre postavljanja nove tem
Molili bi sve posetioce da koriste opciju "Traži" pre postavljanja novih pitanja jer ce na taj nacin najbrze doci do pravog odgovora. Takodje, naslov za novu diskusiju mora da opisuje ukratko problem, dok naslove tipa "Hitno" ili "za doktora..." ne treba koristiti.
ventrikularne ekstrasistole
dg:35 ven.ekstrasistola na dan,samo 5 sves na dan,nije bilo depresije ST segmenta.QT interval nije produzen.Analiza HRV daje nizak nivo rizika,nije bilo pauza duzih od 2.5 sekundi,srednja srcana frekvencija 78,min 46,max 146(penjanje uz stepenice 3 sprat) Terapija:3x1/4 propanolol najmanje 3 meseca.Pijen ga 4 nedelje ali i dalje imam aritmije.Molim da mi date savet.Aritmije su pocele 6 meseci nakon porodjaja i traju 6 mes.HVALA
Znaci promene sa celijama koje su masno i fibrozno/vezivno tkivo/ izmenjene, u prevodu nista sto bi trebalo da vas plasi ali kako je to UZ nalaz i kako se radi o difuznim obostranim promenama, uradite mamografiju!lavita napisao:molim objasnjenje:DOJKE:obostrano sa sonografskim znacima fibrolipomatozne displazije
Pozdrav!
Re: ventrikularne ekstrasistole
Iz vaseg pisanja zakljucujem da se radi o singl-VES, bez fenomena preklapanja na T. Nalaz nije alarmantan ali nije valjda da ste se poslednji put kontrolisali pre 6 meseci a tegobe perzistiraju?! Idite kod kardiologa da vam promeni Th! Ja bih vam ponovio holter-EKG ali bih vam uradio i dopunske pretrage u smislu ishemijskih promena, hormonskog statusa i sl. Ukratko, dopunska dijagnostika i promena terapije.yuyyu napisao:dg:35 ven.ekstrasistola na dan,samo 5 sves na dan,nije bilo depresije ST segmenta.QT interval nije produzen.Analiza HRV daje nizak nivo rizika,nije bilo pauza duzih od 2.5 sekundi,srednja srcana frekvencija 78,min 46,max 146(penjanje uz stepenice 3 sprat) Terapija:3x1/4 propanolol najmanje 3 meseca.Pijen ga 4 nedelje ali i dalje imam aritmije.Molim da mi date savet.Aritmije su pocele 6 meseci nakon porodjaja i traju 6 mes.HVALA
P.S. Poruke u okviru adminovih niko nece videti, postavljajte ih na forumu kao nove teme ili u okviru postojecih-slicnih.
Pozdrav!
-
kima
- Novi član
- Postovi: 18
- Pridružio se: Sub Dec 16, 2006 10:23 pm
- Koliki je zbir brojeva cetiri i pet: 5
- Lokacija: sremska mitrovica
Re: Koristiti opciju "Traži" pre postavljanja nove
VIVOTON S KAPI ZA CEGA SU NAMENJENE
Re: Koristiti opciju "Traži" pre postavljanja nove
Za lecenje niskog krvnog pritiska i posebno "posturalne hipotenzije" tj pada pritiska nakon ustajanja iz horizontalnog polozaja. Lek je homeopatski i bolji je Effortil.kima napisao:VIVOTON S KAPI ZA CEGA SU NAMENJENE
Pitanja postavljajte u okviru postojece ili nove teme, ovde je niko nece videti!!!!!!!!!!!!!!!!!!!
sva pitanja u vezi kalkuloze urotrakta (kamen u bubregu i mokraćnim kanalima) mozete poslati na [email protected]
-
jelena matic
- Novi član
- Postovi: 9
- Pridružio se: Pet Feb 22, 2008 3:29 pm
Pogledajte na: http://www.rxlist.com/cgi/generic/quinidineinj_ad.htm
sva pitanja u vezi kalkuloze urotrakta (kamen u bubregu i mokraćnim kanalima) mozete poslati na [email protected]
UpToDate MedLine:
Copyright 1978-2003 Lexi-Comp, Inc. All rights reserved.
(For additional information see "Chloroquine: Drug information")
U.S. BRAND NAMES – Aralen®
THERAPEUTIC CATEGORY
Amebicide
Antimalarial Agent
DOSING – (Dosage expressed in terms of base):
(For additional information see "Chloroquine: Drug information")
Oral:
Suppression or prophylaxis of malaria:
Children: Administer 5 mg base/kg/week on the same day each week (not to exceed 300 mg base/dose); begin 1-2 weeks prior to exposure; continue for 4 weeks after leaving endemic area; if suppressive therapy is not begun prior to exposure, double the initial loading dose to 10 mg base/kg and give in 2 divided doses 6 hours apart, followed by the usual dosage regimen
Adults: 300 mg/week (base) on the same day each week; begin 1-2 weeks prior to exposure; continue for 4 weeks after leaving endemic area; if suppressive therapy is not begun prior to exposure, double the initial loading dose to 600 mg base and give in 2 divided doses 6 hours apart, followed by the usual dosage regimen
Acute attack:
Children: 10 mg base/kg (maximum dose: 600 mg base) stat, then 5 mg base/kg (maximum dose: 300 mg base) 6 hours later and then 5 mg base/kg/day (maximum daily dose: 300 mg base) once daily for 2 days
Adults: 600 mg base/dose one time, then 300 mg base/dose 6 hours later, and then 300 mg base/dose once daily for 2 days
Extraintestinal amebiasis:
Children: 10 mg base/kg once daily for 2-3 weeks (up to 300 mg base/day)
Adults: 600 mg base/day for 2 days followed by 300 mg base/day for at least 2-3 weeks
Rheumatoid arthritis: Adults: 150 mg base once daily
I.M.:
Severe malaria when oral therapy is not feasible:
Children: 5 mg base/kg (maximum dose: 200 mg base); dose may be repeated in 6 hours; maximum dose: 10 mg base/kg in a 24-hour period
Adults: 200 mg base every 6 hours
DOSAGE FORMS
Injection, solution, as hydrochloride: 50 mg/mL [40 mg base/mL] (5 mL)
Tablet, as phosphate: 250 mg [150 mg base]
Aralen®: 500 mg [300 mg base; film coated]
GENERIC EQUIVALENT AVAILABLE – Yes (tablet)
ADMINISTRATION
Oral: Administer with meals to decrease GI upset; chloroquine phosphate tablets have also been mixed with chocolate syrup or enclosed in gelatin capsules to mask the bitter taste
Parenteral: Cautious administration of frequent small doses by I.M. or S.C. injection in children with severe malaria may reduce risk of severe adverse effects (eg, 2.5 mg base/kg every 4 hours not to exceed 10 mg base/kg in a 24-hour period)
USE – Suppression or chemoprophylaxis of malaria in chloroquine-sensitive areas; treatment of uncomplicated or mild-moderate malaria due to susceptible Plasmodium species, except chloroquine-resistant Plasmodium falciparum; extraintestinal amebiasis; rheumatoid arthritis; discoid lupus erythematosus, scleroderma, pemphigus
ADVERSE REACTIONS
Cardiovascular: Hypotension, EKG changes (T wave depression, widened QRS complex), AV block, cardiomyopathy
Central nervous system: Fatigue, personality changes, headache, confusion, agitation, psychotic episodes, seizures
Dermatologic: Pruritus (particularly the palms, soles, and scalp), hair bleaching, skin eruptions, exfoliative dermatitis
Endocrine & metabolic: Weight loss
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, stomatitis
Hematologic: Blood dyscrasias (neutropenia, aplastic anemia, thrombocytopenia)
Neuromuscular & skeletal: Peripheral neuropathy, neuromyopathy, myalgia
Ocular: Retinopathy, blurred vision, corneal opacity, photophobia, blindness
Otic: Tinnitus, deafness
CONTRAINDICATIONS – Hypersensitivity to chloroquine or any component; retinal or visual field changes; patients with psoriasis
PRECAUTIONS – Use with caution in patients with liver disease, G-6-PD deficiency, or in conjunction with hepatotoxic drugs
DRUG INTERACTIONS – Intradermally administered rabies vaccine; cimetidine increases levels of chloroquine; urinary acidifiers increase the elimination of chloroquine
PREGNANCY RISK FACTOR – C (show table)
MONITORING PARAMETERS – Periodic CBC, examination for muscular weakness and ophthalmologic examination in patients receiving prolonged therapy
PHARMACOKINETICS
Absorption: Oral: Rapid
Distribution: Widely distributed in body tissues including eyes, heart, kidneys, liver, and lungs where retention is prolonged; crosses the placenta; appears in breast milk
Protein binding: 50% to 65%
Metabolism: Partial hepatic
Half-life: 3-5 days
Time to peak serum concentration: Oral: Within 1-2 hours
Elimination: ~70% of dose excreted unchanged in urine; acidification of the urine increases elimination of drug; small amounts of drug may be present in urine months following discontinuation of therapy
Dialysis: Minimally removed by hemodialysis
STABILITY – Protect from light
MECHANISM OF ACTION – Binds to and inhibits DNA and RNA polymerase; interferes with metabolism and hemoglobin utilization by parasites; inhibits prostaglandin effects
PHARMACOKINETICS
Absorption: Oral: Rapid
Distribution: Widely distributed in body tissues including eyes, heart, kidneys, liver, and lungs where retention is prolonged; crosses the placenta; appears in breast milk
Protein binding: 50% to 65%
Metabolism: Partial hepatic
Half-life: 3-5 days
Time to peak serum concentration: Oral: Within 1-2 hours
Elimination: ~70% of dose excreted unchanged in urine; acidification of the urine increases elimination of drug; small amounts of drug may be present in urine months following discontinuation of therapy
Dialysis: Minimally removed by hemodialysis
PATIENT INFORMATION – Report any visual disturbances, muscular weakness, or difficulty in hearing or ringing in the ears; tablets are bitter tasting
EXTEMPORANEOUS PREPARATIONS – A 15 mg chloroquine phosphate/mL suspension (equivalent to 9 mg chloroquine base/mL) is made by pulverizing three Aralen® 500 mg phosphate = 300 mg base/tablet, levigating with 15 mL of a 1:1 vehicle of Ora-Sweet® and Ora-Plus®, and adding vehicle by geometric proportion, levigating until a uniform mixture is obtained; qsad to 100 mL with vehicle, stable for up to 60 days when stored at 5°C or 25°C and protected from light. Label "shake well before using" and "protect from light."
Allen LV Jr and Erickson MA, "Stability of Alprazolam, Chloroquine Phosphate, Cisapride, Enalapril Maleate, and Hydralazine Hydrochloride in Extemporaneously Compounded Oral Liquids,"Am J Health Syst Pharm, 1998, 55(18):1915-20.
[/i]
Copyright 1978-2003 Lexi-Comp, Inc. All rights reserved.
(For additional information see "Chloroquine: Drug information")
U.S. BRAND NAMES – Aralen®
THERAPEUTIC CATEGORY
Amebicide
Antimalarial Agent
DOSING – (Dosage expressed in terms of base):
(For additional information see "Chloroquine: Drug information")
Oral:
Suppression or prophylaxis of malaria:
Children: Administer 5 mg base/kg/week on the same day each week (not to exceed 300 mg base/dose); begin 1-2 weeks prior to exposure; continue for 4 weeks after leaving endemic area; if suppressive therapy is not begun prior to exposure, double the initial loading dose to 10 mg base/kg and give in 2 divided doses 6 hours apart, followed by the usual dosage regimen
Adults: 300 mg/week (base) on the same day each week; begin 1-2 weeks prior to exposure; continue for 4 weeks after leaving endemic area; if suppressive therapy is not begun prior to exposure, double the initial loading dose to 600 mg base and give in 2 divided doses 6 hours apart, followed by the usual dosage regimen
Acute attack:
Children: 10 mg base/kg (maximum dose: 600 mg base) stat, then 5 mg base/kg (maximum dose: 300 mg base) 6 hours later and then 5 mg base/kg/day (maximum daily dose: 300 mg base) once daily for 2 days
Adults: 600 mg base/dose one time, then 300 mg base/dose 6 hours later, and then 300 mg base/dose once daily for 2 days
Extraintestinal amebiasis:
Children: 10 mg base/kg once daily for 2-3 weeks (up to 300 mg base/day)
Adults: 600 mg base/day for 2 days followed by 300 mg base/day for at least 2-3 weeks
Rheumatoid arthritis: Adults: 150 mg base once daily
I.M.:
Severe malaria when oral therapy is not feasible:
Children: 5 mg base/kg (maximum dose: 200 mg base); dose may be repeated in 6 hours; maximum dose: 10 mg base/kg in a 24-hour period
Adults: 200 mg base every 6 hours
DOSAGE FORMS
Injection, solution, as hydrochloride: 50 mg/mL [40 mg base/mL] (5 mL)
Tablet, as phosphate: 250 mg [150 mg base]
Aralen®: 500 mg [300 mg base; film coated]
GENERIC EQUIVALENT AVAILABLE – Yes (tablet)
ADMINISTRATION
Oral: Administer with meals to decrease GI upset; chloroquine phosphate tablets have also been mixed with chocolate syrup or enclosed in gelatin capsules to mask the bitter taste
Parenteral: Cautious administration of frequent small doses by I.M. or S.C. injection in children with severe malaria may reduce risk of severe adverse effects (eg, 2.5 mg base/kg every 4 hours not to exceed 10 mg base/kg in a 24-hour period)
USE – Suppression or chemoprophylaxis of malaria in chloroquine-sensitive areas; treatment of uncomplicated or mild-moderate malaria due to susceptible Plasmodium species, except chloroquine-resistant Plasmodium falciparum; extraintestinal amebiasis; rheumatoid arthritis; discoid lupus erythematosus, scleroderma, pemphigus
ADVERSE REACTIONS
Cardiovascular: Hypotension, EKG changes (T wave depression, widened QRS complex), AV block, cardiomyopathy
Central nervous system: Fatigue, personality changes, headache, confusion, agitation, psychotic episodes, seizures
Dermatologic: Pruritus (particularly the palms, soles, and scalp), hair bleaching, skin eruptions, exfoliative dermatitis
Endocrine & metabolic: Weight loss
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, stomatitis
Hematologic: Blood dyscrasias (neutropenia, aplastic anemia, thrombocytopenia)
Neuromuscular & skeletal: Peripheral neuropathy, neuromyopathy, myalgia
Ocular: Retinopathy, blurred vision, corneal opacity, photophobia, blindness
Otic: Tinnitus, deafness
CONTRAINDICATIONS – Hypersensitivity to chloroquine or any component; retinal or visual field changes; patients with psoriasis
PRECAUTIONS – Use with caution in patients with liver disease, G-6-PD deficiency, or in conjunction with hepatotoxic drugs
DRUG INTERACTIONS – Intradermally administered rabies vaccine; cimetidine increases levels of chloroquine; urinary acidifiers increase the elimination of chloroquine
PREGNANCY RISK FACTOR – C (show table)
MONITORING PARAMETERS – Periodic CBC, examination for muscular weakness and ophthalmologic examination in patients receiving prolonged therapy
PHARMACOKINETICS
Absorption: Oral: Rapid
Distribution: Widely distributed in body tissues including eyes, heart, kidneys, liver, and lungs where retention is prolonged; crosses the placenta; appears in breast milk
Protein binding: 50% to 65%
Metabolism: Partial hepatic
Half-life: 3-5 days
Time to peak serum concentration: Oral: Within 1-2 hours
Elimination: ~70% of dose excreted unchanged in urine; acidification of the urine increases elimination of drug; small amounts of drug may be present in urine months following discontinuation of therapy
Dialysis: Minimally removed by hemodialysis
STABILITY – Protect from light
MECHANISM OF ACTION – Binds to and inhibits DNA and RNA polymerase; interferes with metabolism and hemoglobin utilization by parasites; inhibits prostaglandin effects
PHARMACOKINETICS
Absorption: Oral: Rapid
Distribution: Widely distributed in body tissues including eyes, heart, kidneys, liver, and lungs where retention is prolonged; crosses the placenta; appears in breast milk
Protein binding: 50% to 65%
Metabolism: Partial hepatic
Half-life: 3-5 days
Time to peak serum concentration: Oral: Within 1-2 hours
Elimination: ~70% of dose excreted unchanged in urine; acidification of the urine increases elimination of drug; small amounts of drug may be present in urine months following discontinuation of therapy
Dialysis: Minimally removed by hemodialysis
PATIENT INFORMATION – Report any visual disturbances, muscular weakness, or difficulty in hearing or ringing in the ears; tablets are bitter tasting
EXTEMPORANEOUS PREPARATIONS – A 15 mg chloroquine phosphate/mL suspension (equivalent to 9 mg chloroquine base/mL) is made by pulverizing three Aralen® 500 mg phosphate = 300 mg base/tablet, levigating with 15 mL of a 1:1 vehicle of Ora-Sweet® and Ora-Plus®, and adding vehicle by geometric proportion, levigating until a uniform mixture is obtained; qsad to 100 mL with vehicle, stable for up to 60 days when stored at 5°C or 25°C and protected from light. Label "shake well before using" and "protect from light."
Allen LV Jr and Erickson MA, "Stability of Alprazolam, Chloroquine Phosphate, Cisapride, Enalapril Maleate, and Hydralazine Hydrochloride in Extemporaneously Compounded Oral Liquids,"Am J Health Syst Pharm, 1998, 55(18):1915-20.
[/i]
sva pitanja u vezi kalkuloze urotrakta (kamen u bubregu i mokraćnim kanalima) mozete poslati na [email protected]
U pitanju su grudi> na desnoj bradavici mi je izasao mali plik, e sad, ja ne znam da li je to samo bubuljica ili ima potrebe za nekim ozbiljnijim pregledom?